Objective An endovascular-first approach is usually recommended in femoropopliteal
occlusive disease. However, despite high technical success, plain old balloon angioplasty …

Background Drug‐coated balloon (DCB) angioplasty has emerged as a mainstay of therapy
for the treatment of peripheral arterial disease (PAD) involving the superficial femoral and …

Objectives: This study sought to assess the risk of target lesion revascularization (TLR) and
all-cause death at 12 months and at the maximum available follow-up. Secondary objectives …

Background—In disease of the femoropopliteal artery, paclitaxel-coated balloon (PCB)
therapy improved angiographic outcomes as compared with uncoated balloon (UCB) …

Background Paclitaxel-coated balloons (DCB) are suitable to reduce the risk of restenosis
after angioplasty of atherosclerotic femoropopliteal lesions. However, numerous types of …

Objectives: The authors sought to investigate the efficacy of a drug-coated balloon (DCB) for
treatment of complex femoropopliteal lesions. Background: Superiority of DCBs compared …

Background Paclitaxel drug-coated balloon (DCB) catheter angioplasty is the preferred
treatment for revascularization of femoropopliteal lesions in peripheral artery disease, but …

Objectives: The authors sought to investigate the midterm efficacy and safety of drug-coated
balloon (DCB) in the treatment of severe femoropopliteal artery disease (FPAD) …

Background: Randomized trials of drug-eluting stents (DES) and drug-coated balloons
(DCB) for femoropopliteal interventions reported superior patency rates for both strategies …

Background: Numerous studies have reported favorable outcomes using drug-coated
balloons (DCBs) for treatment of symptomatic peripheral artery disease of the superficial …